Axsome Therapeutics (AXSM) Non-Current Debt (2016 - 2026)

Axsome Therapeutics has disclosed Non-Current Debt across 11 years of filings, most recently posting $117.8 million for Q1 2026.

• Non-Current Debt for Q1 2026 came in at $117.8 million, down 35.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $117.8 million (down 35.02% YoY), and the FY2025 annual result was $117.7 million, down 34.84% from the prior year.
• Non-Current Debt came in at $117.8 million for Q1 2026 at Axsome Therapeutics, roughly flat from $117.7 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $181.4 million in Q1 2025 to a low of $49.3 million in Q1 2022.
• The 5-year median for Non-Current Debt is $147.6 million (2023), against an average of $140.1 million.
• Across the five-year window, Non-Current Debt soared 199.35% in 2023 and slumped 35.02% in 2026, its largest moves.
• Axsome Therapeutics' Non-Current Debt stood at $94.3 million in 2022, then jumped by 88.92% to $178.1 million in 2023, then rose by 1.48% to $180.7 million in 2024, then plunged by 34.84% to $117.7 million in 2025, then advanced by 0.09% to $117.8 million in 2026.
• The last three Non-Current Debt figures came in at $117.8 million (Q1 2026), $117.7 million (Q4 2025), and $117.6 million (Q3 2025), per Business Quant data.